Paige AI
FDA-cleared AI for cancer pathology diagnostics and biomarker discovery.
Paige is the clear specialist for FDA-cleared pathology AI, with proven clinical modules and advanced foundation models. It's a serious investment best suited for large labs and biopharma teams. Smaller operations should weigh the cost and contact-only access before committing. Compared to general-purpose AI or open-source models, Paige offers regulatory-grade, clinically validated tools that are hard to replicate in-house.
Verified 4d ago · liveness 73/100 · cite: rightaichoice.com/tools/paige-ai
- Large pathology labs needing FDA-cleared AI to improve diagnostic throughput and accuracy
- Biopharma companies using AI for biomarker discovery and clinical trial design
- Researchers developing custom computational pathology models with foundation models
- Pathology groups aiming to reduce turnaround time and address pathologist burnout
- Radiology or non-pathology imaging workflows
- Small labs with low slide volumes and limited budgets
- Users seeking fully open-source AI pathology models
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Paige if you're a small lab with tight budgets, need non-cancer pathology support, or prefer transparent pricing over sales calls.
Pricing is not publicly disclosed; you must contact sales, which can lead to substantial upfront costs for licenses and implementation.
Paige's enterprise pricing suits large labs and biopharma with budgets for premium, FDA-cleared AI. For smaller operations, open-source options or per-use cloud AI may be cheaper, but they lack regulatory clearance and clinical validation.
In short
Paige AI — FDA-cleared AI for cancer pathology diagnostics and biomarker discovery. Best for Large pathology labs needing FDA-cleared AI to improve diagnostic throughput and accuracy, Biopharma companies using AI for biomarker discovery and clinical trial design, Researchers developing custom computational pathology models with foundation models. Contact Sales pricing.
What people actually say about Paige AI — is it worth it?
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
29 mentions across 3 sources (Hacker News, YouTube, Lemmy) · researched Aug 6, 2026.
- +FDA-cleared for prostate, breast, and GI cancer detection and grading.
- +Pan-cancer detection across multiple tissue types.
- +Foundation models Virchow2G and PRISM enable custom AI development.
- +Trained on over 1.5 million slides, likely strong generalizability.
- +Voice/text copilot Alba promises hands-free workflow integration.
- −No public community presence or user reviews found anywhere.
- −Contact-only pricing creates opacity; cannot self-serve a trial.
- −Enterprise focus may exclude smaller labs and individual pathologists.
- −Lack of peer validation makes reliability and real-world accuracy unverified.
- −Name collision with another 'Paige' tool causes confusion and noise.
- • Implementation and integration fees likely
- • Potential per-slide or per-case pricing
- • Costs for custom model development and validation
Viability Score
How well maintained and how widely used is Paige AI? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: September 2026
How we score →Key Features
- FDA-cleared prostate cancer detection and grading on H&E whole-slide images
- FDA-cleared breast cancer identification and classification on biopsy and excision slides
- FDA-cleared GI tract benign/malignant detection and classification
- Pan-cancer detection across multiple tissue types, including rare cancers
- Paige Alba multi-modal copilot with voice and text commands
- Real-time AI insights during pathology review
- Foundation models: Virchow, Virchow2, Virchow2G, Virchow2G-Mini, PRISM
- Pre-built pan-cancer AI modules for drug discovery
- OmniScreen molecular biomarker discovery from H&E slides
- Custom AI model development services
- Regulatory strategy and commercialization support
- Trained on 1.5 million slides
- Whole-slide image analysis for H&E-stained samples
- AI-assisted diagnostic decision support for pathologists
- Multi-modal copilot integration with existing pathology workflows
About Paige AI
Paige AI is a clinical-grade artificial intelligence platform built exclusively for cancer pathology. It provides FDA-cleared diagnostic applications that assist pathologists in detecting and grading prostate, breast, and gastrointestinal cancers on H&E-stained whole-slide images. The PanCancer Suite, trained on over 1.5 million slides, helps identify subtle malignancies across multiple tissue types, including rare cancers. For researchers and biopharma, Paige offers foundation models like Virchow, Virchow2, Virchow2G, Virchow2G-Mini, and PRISM, plus OmniScreen services for molecular biomarker discovery directly from tissue samples. The platform also includes Paige Alba, a multi-modal copilot that accepts voice and text commands to provide real-time insights and streamline diagnostic workflows. Designed to assist—not replace—the pathologist, Paige's applications fit into existing workflows to reduce turnaround time and address pathologist burnout. The Prostate, Breast, and GI Suites target specific clinical areas, while the PanCancer Suite leverages Virchow for broad cancer detection. For life sciences, Paige licenses its foundation models and offers pre-built AI modules for therapeutic targeting, novel biomarker identification, and optimized clinical trial design. Services include custom AI development, regulatory strategy, and commercialization support. Paige is not a general-purpose AI tool; it focuses exclusively on cancer pathology, making it a specialized partner for large labs and biopharma companies. Pricing is not publicly disclosed and requires contacting sales, which may be a barrier for smaller labs.
Behind the Verdict
Paige sits in a unique position: it's one of the few companies with FDA-cleared AI for pathology, which gives it a regulatory moat that general-purpose AI tools can't touch. The Prostate, Breast, and GI Suites are purpose-built for specific diagnostic tasks, and the PanCancer Suite trained on 1.5 million slides is a strong differentiator for detecting rare cancers. The foundation models (Virchow family, PRISM) are a major asset for biopharma researchers who want to build custom models without starting from scratch. The biggest strength is the regulatory clearance—this isn't a research toy. Pathologists can use it in clinical practice, and the real-time insights from Paige Alba (with voice and text commands) fit into the diagnostic workflow. For biopharma, the OmniScreen service for molecular biomarkers (like MSI, HER2) from H&E slides could speed up drug development and clinical trials. Weaknesses: Pricing is opaque—contact sales only, which is a red flag for smaller labs. The platform is narrowly focused on cancer pathology; it won't help with radiology or other imaging. The foundation models are proprietary, so you're locked into Paige's ecosystem for development. Also, the evidence doesn't mention integration with common LIS or scanner vendors, which could be a hurdle for some labs. Where it fits: large pathology labs that need regulatory-grade AI to handle high volumes, and biopharma companies doing biomarker discovery or clinical trial design. Where it doesn't: small labs with low slide volumes, researchers wanting open-source models, or anyone outside cancer pathology. Compared to similar tools like PathAI or Ibex, Paige's FDA clearances and foundation model breadth give it an edge, but the contact-only pricing makes it hard to compare apples-to-apples. If you're a large lab, the trial request is worth it; if you're small, explore alternatives first.
Researching Paige AI? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Paige AI actually fits — and what changes day-one when you adopt it.
Implement Paige Prostate Suite to assist pathologists in detecting prostate cancer on H&E needle biopsies.
Outcome: Faster, more accurate diagnosis, reduced workload, and improved patient outcomes.
Use OmniScreen to discover molecular biomarkers from tissue samples for clinical trial design.
Outcome: Accelerated biomarker identification, potentially reducing trial duration and costs.
License Virchow2 foundation model to train custom models for niche cancer detection.
Outcome: Reduced development time and cost compared to building from scratch.
Use Cases
- Prostate cancer detection and grading on H&E needle biopsies
- Breast cancer identification in biopsy and excision specimens
- GI tract condition detection (colon, gastric, etc.)
- Pan-cancer detection including rare cancer types
- Molecular biomarker discovery (e.g., MSI, HER2) via OmniScreen
- Custom AI model development for pharmaceutical drug discovery
Models Under the Hood
as of 2026-08-30
Limitations
- Paige requires contacting sales for pricing, so cost transparency is minimal.
- The platform is specialized for cancer pathology and does not cover other imaging domains.
- It relies on H&E-stained slides, so labs using other stains won't benefit.
- There's no public integration list, which may complicate adoption in labs with specific scanner or LIS requirements.
- Foundation models are proprietary, limiting flexibility for some researchers.
as of 2026-08-29
Verification history
We have re-verified Paige AI 18 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 18 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Paige AI's pricing actually pencils out — and where peers do it cheaper.
Paige's enterprise pricing suits large labs and biopharma with budgets for premium, FDA-cleared AI. For smaller operations, open-source options or per-use cloud AI may be cheaper, but they lack regulatory clearance and clinical validation.
Setup time & first value
How long it actually takes to get something useful out of Paige AI — broken out by persona, not the marketing-page minute.
Implementation time varies: for large labs, integrating with existing pathology workflows may take several weeks to months due to validation and staff training. Smaller pilot projects could yield first insights within days to weeks. Contact sales for a tailored plan.
Switching to or from Paige AI
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From Manual or Traditional Workflow: Paige AI can be added as an assistive tool without replacing existing processes; validation and training are key.
Resources & Guides
- Resourcepaige.ai
How Foundation Models Can Transform Pathology — Paige.ai
Helpful link from paige.ai
- Resourcepaige.ai
Transforming Drug Discovery and Scientific Innovation with Foundation Model Technology — Paige.ai
Helpful link from paige.ai
- Resourcepaige.ai
Breaking Through the Complexity of Cancer Detection — Paige.ai
Helpful link from paige.ai
- Resourcepaige.ai
Embracing AI: The Third Revolution in Pathology — Paige.ai
Helpful link from paige.ai
- Resourcepaige.ai
The State of Digital Pathology and AI in 2024 — Paige.ai
Helpful link from paige.ai
- Resourcepaige.ai
The Virchow Foundation Model, Explained: A Q&A with an AI Scientist — Paige.ai
Helpful link from paige.ai
Tutorials & Learning
Official links
Frequently Asked Questions
Best-of guides
Topics
Used Paige AI? Help shape our editorial sentiment research.